Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Rheumatoid Arthritis

  Free Subscription


Articles published in Arthritis Res Ther

Retrieve available abstracts of 158 articles:
HTML format



Single Articles


    November 2022
  1. LI Q, Li Y, Liang B, Xu R, et al
    Rheumatoid arthritis sera antibodies to citrullinated collagen type II bind to joint cartilage.
    Arthritis Res Ther. 2022;24:257.
    PubMed     Abstract available


  2. PARANTAINEN J, Barreto G, Koivuniemi R, Kautiainen H, et al
    The biological activity of serum bacterial lipopolysaccharides associates with disease activity and likelihood of achieving remission in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:256.
    PubMed     Abstract available


  3. LI X, Cesta A, Movahedi M, Bombardier C, et al
    Late-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis: results from the Ontario Best Practices Research Initiative.
    Arthritis Res Ther. 2022;24:255.
    PubMed     Abstract available


  4. PARK JS, Yang SC, Jeong HY, Lee SY, et al
    EC-18 prevents autoimmune arthritis by suppressing inflammatory cytokines and osteoclastogenesis.
    Arthritis Res Ther. 2022;24:254.
    PubMed     Abstract available


  5. BERGMAN M, Tundia N, Martin N, Suboticki JL, et al
    Correction: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
    Arthritis Res Ther. 2022;24:248.
    PubMed    


  6. YAO Y, Cai X, Zhang M, Zhang X, et al
    PSTPIP2 regulates synovial macrophages polarization and dynamics via ERbeta in the joint microenvironment.
    Arthritis Res Ther. 2022;24:247.
    PubMed     Abstract available


  7. HEIN TR, Peterson L, Bartikoski BJ, Portes J, et al
    Response to Comment on "The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis".
    Arthritis Res Ther. 2022;24:246.
    PubMed    


  8. MINAMINO H, Torii M, Katsushima M, Fujita Y, et al
    Comment on "The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis".
    Arthritis Res Ther. 2022;24:245.
    PubMed     Abstract available


    October 2022
  9. ZHU J, Niu Z, Alfredsson L, Klareskog L, et al
    Response to Comment "Sex-specific exposures and sex-combined outcomes in two-sample Mendelian randomization may mislead the causal inference" on "Age at menarche, age at natural menopause, and risk of rheumatoid arthritis-a Mendelian randomization stu
    Arthritis Res Ther. 2022;24:239.
    PubMed    


  10. CHOI B, Park HJ, Song YK, Oh YJ, et al
    Correction: The risk of newly diagnosed cancer in patients with rheumatoid arthritis by TNF inhibitor use: a nationwide cohort study.
    Arthritis Res Ther. 2022;24:238.
    PubMed    


  11. WANG Z, Lu J
    Sex-specific exposures and sex-combined outcomes in two-sample Mendelian randomization may mislead the causal inference.
    Arthritis Res Ther. 2022;24:237.
    PubMed     Abstract available


  12. CAFARO G, Petito E, Bistoni O, Falcinelli E, et al
    Methotrexate improves endothelial function in early rheumatoid arthritis patients after 3 months of treatment.
    Arthritis Res Ther. 2022;24:236.
    PubMed     Abstract available


  13. LU Y, Hao C, Yu S, Ma Z, et al
    Cationic amino acid transporter-1 (CAT-1) promotes fibroblast-like synoviocyte proliferation and cytokine secretion by taking up L-arginine in rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:234.
    PubMed     Abstract available


  14. KOO BS, Eun S, Shin K, Hong S, et al
    Differences in trajectory of disease activity according to biologic and targeted synthetic disease-modifying anti-rheumatic drug treatment in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:233.
    PubMed     Abstract available


  15. KROOS S, Kampstra ASB, Toes REM, Slot LM, et al
    Absence of Epstein-Barr virus DNA in anti-citrullinated protein antibody-expressing B cells of patients with rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:230.
    PubMed     Abstract available


  16. MIYAMA K, Bise R, Ikemura S, Kai K, et al
    Deep learning-based automatic-bone-destruction-evaluation system using contextual information from other joints.
    Arthritis Res Ther. 2022;24:227.
    PubMed     Abstract available


    September 2022
  17. KAWABE A, Yamagata K, Kato S, Nakano K, et al
    Role of DNA dioxygenase Ten-Eleven translocation 3 (TET3) in rheumatoid arthritis progression.
    Arthritis Res Ther. 2022;24:222.
    PubMed     Abstract available


  18. IBRAHIM F, Ma M, Scott DL, Scott IC, et al
    Defining the relationship between pain intensity and disease activity in patients with rheumatoid arthritis: a secondary analysis of six studies.
    Arthritis Res Ther. 2022;24:218.
    PubMed     Abstract available


  19. NOACK M, Miossec P
    Synoviocytes and skin fibroblasts show opposite effects on IL-23 production and IL-23 receptor expression during cell interactions with immune cells.
    Arthritis Res Ther. 2022;24:220.
    PubMed     Abstract available


  20. CHEN N, Fan B, He Z, Yu X, et al
    Identification of HBEGF+ fibroblasts in the remission of rheumatoid arthritis by integrating single-cell RNA sequencing datasets and bulk RNA sequencing datasets.
    Arthritis Res Ther. 2022;24:215.
    PubMed     Abstract available


    August 2022
  21. RUBBERT-ROTH A, Furst DE, Fiore S, Praestgaard A, et al
    Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab.
    Arthritis Res Ther. 2022;24:207.
    PubMed     Abstract available


  22. SENARD T, Flouri I, Vuckovic F, Papadaki G, et al
    Baseline IgG-Fc N-glycosylation profile is associated with long-term outcome in a cohort of early inflammatory arthritis patients.
    Arthritis Res Ther. 2022;24:206.
    PubMed     Abstract available


  23. HEDENSTIERNA L, Hedstrom AK, Klareskog L, Di Giuseppe D, et al
    Neither low social support nor low decision latitude at work is associated with disease remission among patients with rheumatoid arthritis: results from the Swedish EIRA study.
    Arthritis Res Ther. 2022;24:203.
    PubMed     Abstract available


  24. NAVARRO-MILLAN I, Xie F, Crowson CS, Safford MM, et al
    Comparing cardiovascular risk of patients with rheumatoid arthritis within the Social Security Disability Insurance with those commercially insured.
    Arthritis Res Ther. 2022;24:202.
    PubMed     Abstract available


  25. GERNERT M, Schmalzing M, Tony HP, Strunz PP, et al
    Calprotectin (S100A8/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapy.
    Arthritis Res Ther. 2022;24:200.
    PubMed     Abstract available


  26. FUKUE R, Okazaki Y, Gono T, Kuwana M, et al
    Abatacept downregulates Fcgamma receptor I on circulating monocytes: a potential therapeutic mechanism in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:194.
    PubMed     Abstract available


  27. CONTRERAS-YANEZ I, Guaracha-Basanez GA, Cuevas-Montoya M, de Jesus Hernandez-Bautista J, et al
    Early persistence on therapy impacts drug-free remission: a case-control study in a cohort of Hispanic patients with recent-onset rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:193.
    PubMed     Abstract available


  28. CHOI B, Park HJ, Song YK, Oh YJ, et al
    The risk of newly diagnosed cancer in patients with rheumatoid arthritis by TNF inhibitor use: a nationwide cohort study.
    Arthritis Res Ther. 2022;24:191.
    PubMed     Abstract available


  29. FUKUDA W, Kadoya M, Omoto A, Yanagida T, et al
    Treatment of rheumatoid arthritis and its outcomes in an aging society: a single-center cohort study in Japan from 2011 to 2020.
    Arthritis Res Ther. 2022;24:190.
    PubMed     Abstract available


  30. DU Y, Cui R, Tian N, Chen M, et al
    Regulation of type I interferon signature by VGLL3 in the fibroblast-like synoviocytes of rheumatoid arthritis patients via targeting the Hippo pathway.
    Arthritis Res Ther. 2022;24:188.
    PubMed     Abstract available


  31. SYSOJEV AO, Frisell T, Delcoigne B, Saevarsdottir S, et al
    Does persistence to methotrexate treatment in early rheumatoid arthritis have a familial component?
    Arthritis Res Ther. 2022;24:185.
    PubMed     Abstract available


  32. PODEWSKI AF, Glimm AM, Fischer I, Bruyn GAW, et al
    The MCP2 and the wrist plus two extensor compartments are the most affected and responsive joints/tendons out of the US7 score in patients with rheumatoid arthritis-an observational study.
    Arthritis Res Ther. 2022;24:183.
    PubMed     Abstract available


  33. PARK E, Ito K, Iqbal R, Amigues I, et al
    Prospective changes in diastolic function in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:184.
    PubMed     Abstract available


    July 2022
  34. JEONG S, Choi S, Park SM, Kim J, et al
    Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study.
    Arthritis Res Ther. 2022;24:180.
    PubMed     Abstract available


  35. WESTERLIND H, Dukuzimana J, Lu X, Alfredsson L, et al
    Investigation of the association between coffee and risk of RA-results from the Swedish EIRA study.
    Arthritis Res Ther. 2022;24:178.
    PubMed     Abstract available


  36. GREMESE E, Tolusso B, Petricca L, Di Mario C, et al
    Correction: Peripheral blood CD4(pos)CD25(pos)FoxP3(pos) cells and inflammatory cytokines as biomarkers of response in rheumatoid arthritis patients treated with CTLA4-Ig.
    Arthritis Res Ther. 2022;24:177.
    PubMed    


  37. HEIN TR, Peterson L, Bartikoski BJ, Portes J, et al
    The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis.
    Arthritis Res Ther. 2022;24:171.
    PubMed     Abstract available


  38. PENG Y, Wu X, Zhang S, Deng C, et al
    The potential roles of type I interferon activated neutrophils and neutrophil extracellular traps (NETs) in the pathogenesis of primary Sjogren's syndrome.
    Arthritis Res Ther. 2022;24:170.
    PubMed     Abstract available


  39. RINCON-AREVALO H, Burbano C, Atehortua L, Rojas M, et al
    Modulation of B cell activation by extracellular vesicles and potential alteration of this pathway in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:169.
    PubMed     Abstract available


  40. SCIACCA E, Surace AEA, Alaimo S, Pulvirenti A, et al
    Network analysis of synovial RNA sequencing identifies gene-gene interactions predictive of response in rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:166.
    PubMed     Abstract available


  41. DUONG SQ, Crowson CS, Athreya A, Atkinson EJ, et al
    Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: a machine learning approach using clinical trial data.
    Arthritis Res Ther. 2022;24:162.
    PubMed     Abstract available


    June 2022
  42. JUNG SM, Han M, Kim EH, Jung I, et al
    Comparison of developing tuberculosis following tumor necrosis factor inhibition and interleukin-6 inhibition in patients with rheumatoid arthritis: a nationwide observational study in South Korea, 2013-2018.
    Arthritis Res Ther. 2022;24:157.
    PubMed     Abstract available


  43. BERGMAN M, Tundia N, Martin N, Suboticki JL, et al
    Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
    Arthritis Res Ther. 2022;24:155.
    PubMed     Abstract available


  44. DAKKAK YJ, van Dijk BT, Jansen FP, Wisse LJ, et al
    Evidence for the presence of synovial sheaths surrounding the extensor tendons at the metacarpophalangeal joints: a microscopy study.
    Arthritis Res Ther. 2022;24:154.
    PubMed     Abstract available


  45. SAKELLARIOU G, Scire CA, Rumi F, Carrara G, et al
    Influence of initial glucocorticoid co-medication on mortality and hospitalization in early inflammatory arthritis: an investigation by record linkage of clinical and administrative databases.
    Arthritis Res Ther. 2022;24:144.
    PubMed     Abstract available


  46. ELISA G, Tolusso B, Petricca L, Di Mario C, et al
    Peripheral blood CD4(pos)CD25(pos)FoxP3(pos) cells and inflammatory cytokines as biomarkers of response in rheumatoid arthritis patients treated with CTLA4-Ig.
    Arthritis Res Ther. 2022;24:143.
    PubMed     Abstract available


  47. SAKAI R, Tanaka E, Majima M, Harigai M, et al
    Unincreased risk of hospitalized infection under targeted therapies versus methotrexate in elderly patients with rheumatoid arthritis: a retrospective cohort study.
    Arthritis Res Ther. 2022;24:135.
    PubMed     Abstract available


  48. ZENG X, Liu J, Liu X, Wu L, et al
    Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study.
    Arthritis Res Ther. 2022;24:136.
    PubMed     Abstract available


  49. SHODA J, Tanaka S, Etori K, Hattori K, et al
    Semaphorin 3G exacerbates joint inflammation through the accumulation and proliferation of macrophages in the synovium.
    Arthritis Res Ther. 2022;24:134.
    PubMed     Abstract available


  50. SCHMITT C, Brockwell L, Giraudon M, Zucchetto M, et al
    Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study.
    Arthritis Res Ther. 2022;24:133.
    PubMed     Abstract available


  51. BERTSIAS A, Avgoustidis N, Papalopoulos I, Repa A, et al
    Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study.
    Arthritis Res Ther. 2022;24:132.
    PubMed     Abstract available


  52. KASHIWADO Y, Kiyohara C, Kimoto Y, Nagano S, et al
    Clinical course of patients with rheumatoid arthritis who continue or discontinue biologic therapy after hospitalization for infection: a retrospective observational study.
    Arthritis Res Ther. 2022;24:131.
    PubMed     Abstract available


    May 2022
  53. MARTIN-GONZALEZ C, Martin-Folgueras T, Quevedo-Abeledo JC, de Vera-Gonzalez A, et al
    Apolipoprotein C-III is linked to the insulin resistance and beta-cell dysfunction that are present in rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:126.
    PubMed     Abstract available


  54. KNITZA J, Tascilar K, Vuillerme N, Eimer E, et al
    Accuracy and tolerability of self-sampling of capillary blood for analysis of inflammation and autoantibodies in rheumatoid arthritis patients-results from a randomized controlled trial.
    Arthritis Res Ther. 2022;24:125.
    PubMed     Abstract available


  55. SHI L, Wang J, Guo HX, Han XL, et al
    Circulating Th2 cell reduction and Th1/Th2 imbalance are correlated with primary Sjogren's syndrome-associated interstitial lung disease.
    Arthritis Res Ther. 2022;24:121.
    PubMed     Abstract available


  56. HERTRAMPF S, Klotsche J, Schefer Q, Glimm AM, et al
    Monitoring of patients with rheumatoid arthritis by indocyanine green (ICG)-enhanced fluorescence optical imaging treated with anti-TNFalpha therapy.
    Arthritis Res Ther. 2022;24:117.
    PubMed     Abstract available


  57. QIN Y, Wang Y, Meng F, Feng M, et al
    Identification of biomarkers by machine learning classifiers to assist diagnose rheumatoid arthritis-associated interstitial lung disease.
    Arthritis Res Ther. 2022;24:115.
    PubMed     Abstract available


  58. KEINDL M, Davies R, Bergum B, Brun JG, et al
    Impaired activation of STAT5 upon IL-2 stimulation in Tregs and elevated sIL-2R in Sjogren's syndrome.
    Arthritis Res Ther. 2022;24:101.
    PubMed     Abstract available


  59. SIGAUX J, Mathieu S, Nguyen Y, Sanchez P, et al
    Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis.
    Arthritis Res Ther. 2022;24:100.
    PubMed     Abstract available


    April 2022
  60. DE ARMAS-RILLO L, Quevedo-Abeledo JC, Hernandez-Hernandez V, de Vera-Gonzalez A, et al
    The angiopoietin-like protein 4, apolipoprotein C3, and lipoprotein lipase axis is disrupted in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:99.
    PubMed     Abstract available


  61. KONDO F, Sugihara T, Umezawa N, Hasegawa H, et al
    Associated factors with poor treatment response to initial glucocorticoid therapy in patients with adult-onset Still's disease.
    Arthritis Res Ther. 2022;24:92.
    PubMed     Abstract available


  62. SHARMA S, Plant D, Bowes J, Macgregor A, et al
    HLA-DRB1 haplotypes predict cardiovascular mortality in inflammatory polyarthritis independent of CRP and anti-CCP status.
    Arthritis Res Ther. 2022;24:90.
    PubMed     Abstract available


  63. BARTLETT SJ, Bingham CO, van Vollenhoven R, Murray C, et al
    The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials.
    Arthritis Res Ther. 2022;24:83.
    PubMed     Abstract available


    March 2022
  64. SAKURABA K, Omori Y, Kai K, Terada K, et al
    Risk factor analysis of perioperative complications in patients with rheumatoid arthritis undergoing primary cervical spine surgery.
    Arthritis Res Ther. 2022;24:79.
    PubMed     Abstract available


  65. JOO YB, Lee KB, Sul B, Lee HS, et al
    Effect of resistance exercise on serum leptin levels in a prospective longitudinal study of women patients with rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:76.
    PubMed     Abstract available


  66. VAN DER LEEUW MS, Messelink MA, Tekstra J, Medina O, et al
    Using real-world data to dynamically predict flares during tapering of biological DMARDs in rheumatoid arthritis: development, validation, and potential impact of prediction-aided decisions.
    Arthritis Res Ther. 2022;24:74.
    PubMed     Abstract available


  67. HUSNI ME, Deodhar A, Schwartzman S, Chakravarty SD, et al
    Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Arthritis Res Ther. 2022;24:73.
    PubMed     Abstract available


  68. VITTECOQ O, Guillou C, Hardouin J, Gerard B, et al
    Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combination.
    Arthritis Res Ther. 2022;24:72.
    PubMed     Abstract available


  69. KENNEY HM, Wu CL, Loiselle AE, Xing L, et al
    Single-cell transcriptomics of popliteal lymphatic vessels and peripheral veins reveals altered lymphatic muscle and immune cell populations in the TNF-Tg arthritis model.
    Arthritis Res Ther. 2022;24:64.
    PubMed     Abstract available


  70. OCHI S, Sonomoto K, Nakayamada S, Tanaka Y, et al
    Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry.
    Arthritis Res Ther. 2022;24:61.
    PubMed     Abstract available


    February 2022
  71. MILLIER MJ, Fanning NC, Frampton C, Stamp LK, et al
    Plasma interleukin-23 and circulating IL-17A(+)IFNgamma(+) ex-Th17 cells predict opposing outcomes of anti-TNF therapy in rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:57.
    PubMed     Abstract available


  72. GOUZE H, Aegerter P, Said-Nahal R, Zins M, et al
    Rheumatoid arthritis, as a clinical disease, but not rheumatoid arthritis-associated autoimmunity, is linked to cardiovascular events.
    Arthritis Res Ther. 2022;24:56.
    PubMed     Abstract available


  73. SIMONS G, Caplan J, DiSantostefano RL, Veldwijk J, et al
    Systematic review of quantitative preference studies of treatments for rheumatoid arthritis among patients and at-risk populations.
    Arthritis Res Ther. 2022;24:55.
    PubMed     Abstract available


  74. FUJIWARA T, Kondo M, Yamada H, Haraguchi A, et al
    Factors affecting patient satisfaction related to cost and treatment effectiveness in rheumatoid arthritis: results from the multicenter observational cohort study, FRANK Registry.
    Arthritis Res Ther. 2022;24:53.
    PubMed     Abstract available


  75. AHMAD HA, Baker JF, Conaghan PG, Emery P, et al
    Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept.
    Arthritis Res Ther. 2022;24:47.
    PubMed     Abstract available


  76. SORENSEN AS, Andersen MN, Juul-Madsen K, Brokso AD, et al
    Tumor necrosis factor alpha neutralization attenuates immune checkpoint inhibitor-induced activation of intermediate monocytes in synovial fluid mononuclear cells from patients with inflammatory arthritis.
    Arthritis Res Ther. 2022;24:43.
    PubMed     Abstract available


  77. FIECHTER RH, Bolt JW, van de Sande MGH, Aalbers CJ, et al
    Ultrasound-guided lymph node biopsy sampling to study the immunopathogenesis of rheumatoid arthritis: a well-tolerated valuable research tool.
    Arthritis Res Ther. 2022;24:36.
    PubMed     Abstract available


    January 2022
  78. WU YY, Li XF, Wu S, Niu XN, et al
    Role of the S100 protein family in rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:35.
    PubMed     Abstract available


  79. REBIC N, Munro S, Garg R, Hazlewood G, et al
    "The medications are the decision-makers..." Making reproductive and medication use decisions among female patients with rheumatoid arthritis: a constructivist grounded theory.
    Arthritis Res Ther. 2022;24:31.
    PubMed     Abstract available


  80. GARCIA-MONTOYA L, Nam JL, Duquenne L, Villota-Eraso C, et al
    Prioritising referrals of individuals at-risk of RA: guidance based on results of a 10-year national primary care observational study.
    Arthritis Res Ther. 2022;24:26.
    PubMed     Abstract available


  81. DE FRANCA NR, Menard HA, Lora M, Zhou Z, et al
    Characterization and use of the ECV304 autoantigenic citrullinome to understand anti-citrullinated protein/peptide autoantibodies in rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:23.
    PubMed     Abstract available


  82. BROUWERS H, von Hegedus JH, van der Linden E, Mahdad R, et al
    Hyaluronidase treatment of synovial fluid is required for accurate detection of inflammatory cells and soluble mediators.
    Arthritis Res Ther. 2022;24:18.
    PubMed     Abstract available


  83. VERSTAPPEN M, van Steenbergen HW, de Jong PHP, van der Helm-van Mil AHM, et al
    Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution.
    Arthritis Res Ther. 2022;24:4.
    PubMed     Abstract available


  84. MEEHAN M, Shah A, Lobo J, Oates J, et al
    Validation of an algorithm to identify incident interstitial lung disease in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:2.
    PubMed     Abstract available


  85. BINGHAM CO 3RD, Walker D, Nash P, Lee SJ, et al
    The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies.
    Arthritis Res Ther. 2022;24:11.
    PubMed     Abstract available


  86. SUGIYAMA T, Furuta S, Hiraguri M, Ikeda K, et al
    Latent class analysis of 216 patients with adult-onset Still's disease.
    Arthritis Res Ther. 2022;24:7.
    PubMed     Abstract available


    December 2021
  87. CUTOLO M, Soldano S, Gotelli E, Montagna P, et al
    CTLA4-Ig treatment induces M1-M2 shift in cultured monocyte-derived macrophages from healthy subjects and rheumatoid arthritis patients.
    Arthritis Res Ther. 2021;23:306.
    PubMed     Abstract available


  88. ZHANG X, Feng R, Zhao J, Wang Y, et al
    Salivary gland ultrasonography in primary Sjogren's syndrome from diagnosis to clinical stratification: a multicentre study.
    Arthritis Res Ther. 2021;23:305.
    PubMed     Abstract available


  89. MOLINA COLLADA J, Lopez Gloria K, Castrejon I, Nieto-Gonzalez JC, et al
    Ultrasound in clinically suspect arthralgia: the role of power Doppler to predict rheumatoid arthritis development.
    Arthritis Res Ther. 2021;23:299.
    PubMed     Abstract available


  90. LI R, Liu X, Chen G, Tang G, et al
    Clinical phenotypes and prognostic factors of adult-onset Still's disease: data from a large inpatient cohort.
    Arthritis Res Ther. 2021;23:300.
    PubMed     Abstract available


    November 2021
  91. GEROSSIER E, Nayar S, Froidevaux S, Smith CG, et al
    Cenerimod, a selective S1P1 receptor modulator, improves organ-specific disease outcomes in animal models of Sjogren's syndrome.
    Arthritis Res Ther. 2021;23:289.
    PubMed     Abstract available


  92. DOUMEN M, De Cock D, Pazmino S, Bertrand D, et al
    Correction to: Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:285.
    PubMed    


  93. REISER C, Klotsche J, Hospach A, Berendes R, et al
    First-year follow-up of children with chronic nonbacterial osteomyelitis-an analysis of the German National Pediatric Rheumatologic Database from 2009 to 2018.
    Arthritis Res Ther. 2021;23:281.
    PubMed     Abstract available


  94. LEE SY, Ibrahim F, Tom BDM, Nikiphorou E, et al
    Baseline predictors of remission, pain and fatigue in rheumatoid arthritis: the TITRATE trial.
    Arthritis Res Ther. 2021;23:278.
    PubMed     Abstract available


    October 2021
  95. KOPPEJAN H, Hameetman M, Beyrend G, van Unen V, et al
    Immunoprofiling of early, untreated rheumatoid arthritis using mass cytometry reveals an activated basophil subset inversely linked to ACPA status.
    Arthritis Res Ther. 2021;23:272.
    PubMed     Abstract available


  96. MATSUSHITA T, Otani K, Oto Y, Takahashi Y, et al
    Sustained microglial activation in the area postrema of collagen-induced arthritis mice.
    Arthritis Res Ther. 2021;23:273.
    PubMed     Abstract available


  97. MICHAEL D, Diederik C, Sofia P, Delphine B, et al
    Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:269.
    PubMed     Abstract available


  98. LECHTENBOEHMER CA, Burkard T, Reichenbach S, Walker UA, et al
    Increased radiographic progression of distal hand osteoarthritis occurring during biologic DMARD monotherapy for concomitant rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:267.
    PubMed     Abstract available


  99. YIN G, Yang C, Wu G, Yu X, et al
    The protein-protein interaction between connective tissue growth factor and annexin A2 is relevant to pannus formation in rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:266.
    PubMed     Abstract available


  100. TSEN SD, Springer LE, Sharmah Gautam K, Tang R, et al
    Non-invasive monitoring of arthritis treatment response via targeting of tyrosine-phosphorylated annexin A2 in chondrocytes.
    Arthritis Res Ther. 2021;23:265.
    PubMed     Abstract available


  101. COSTELLO RE, Humphreys JH, Sergeant JC, Haris M, et al
    Correction to: Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the Preclinical EValuation of Novel Targ
    Arthritis Res Ther. 2021;23:263.
    PubMed    


  102. GAN Y, Sun Y, Jin J, Wang Y, et al
    bFGF could be a biomarker of malignancy in RS3PE syndrome: an ambispective single-center cohort analysis of 51 patients.
    Arthritis Res Ther. 2021;23:261.
    PubMed     Abstract available


  103. HAN S, Kim NR, Kang JW, Eun JS, et al
    Radial BMD and serum CTX-I can predict the progression of carotid plaque in rheumatoid arthritis: a 3-year prospective cohort study.
    Arthritis Res Ther. 2021;23:258.
    PubMed     Abstract available


  104. WANG Q, Che N, Lu C, Sun X, et al
    Correlation of peripheral CD4+GranzB+CTLs with disease severity in patients with primary Sjogren's syndrome.
    Arthritis Res Ther. 2021;23:257.
    PubMed     Abstract available


  105. WAHBI A, Tessoulin B, Bretonniere C, Boileau J, et al
    Catastrophic adult-onset Still's disease as a distinct life-threatening clinical subset: case-control study with dimension reduction analysis.
    Arthritis Res Ther. 2021;23:256.
    PubMed     Abstract available


  106. LEE S, Kang S, Eun Y, Won HH, et al
    Machine learning-based prediction model for responses of bDMARDs in patients with rheumatoid arthritis and ankylosing spondylitis.
    Arthritis Res Ther. 2021;23:254.
    PubMed     Abstract available


    September 2021
  107. XU X, Geng L, Chen C, Kong W, et al
    Olfactory impairment in patients with primary Sjogren's syndrome and its correlation with organ involvement and immunological abnormalities.
    Arthritis Res Ther. 2021;23:250.
    PubMed     Abstract available


  108. FLEISCHMANN RM, Alvarez DF, Bock AE, Cronenberger C, et al
    Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira(R)) or continuing biosimilar therapy: week 52-92 data from a randomized,
    Arthritis Res Ther. 2021;23:248.
    PubMed     Abstract available


  109. KIM GH, Park YJ
    Accelerated diastolic dysfunction in premenopausal women with rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:247.
    PubMed     Abstract available


  110. PETERSON MN, Dykhoff HJ, Crowson CS, Davis JM 3rd, et al
    Risk of rheumatoid arthritis diagnosis in statin users in a large nationwide US study.
    Arthritis Res Ther. 2021;23:244.
    PubMed     Abstract available


  111. RIGBY W, Buckner JH, Louis Bridges S Jr, Nys M, et al
    HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA.
    Arthritis Res Ther. 2021;23:245.
    PubMed     Abstract available


  112. HAN Y, Wang J, Li S, Li Y, et al
    Isopsoralen ameliorates rheumatoid arthritis by targeting MIF.
    Arthritis Res Ther. 2021;23:243.
    PubMed     Abstract available


  113. MARKLEIN B, Jenning M, Konthur Z, Haupl T, et al
    The citrullinated/native index of autoantibodies against hnRNP-DL predicts an individual "window of treatment success" in RA patients.
    Arthritis Res Ther. 2021;23:239.
    PubMed     Abstract available


  114. MEASE PJ, Stryker S, Liu M, Salim B, et al
    Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry.
    Arthritis Res Ther. 2021;23:236.
    PubMed     Abstract available


  115. REIJM S, Kissel T, Stoeken-Rijsbergen G, Slot LM, et al
    Cross-reactivity of IgM anti-modified protein antibodies in rheumatoid arthritis despite limited mutational load.
    Arthritis Res Ther. 2021;23:230.
    PubMed     Abstract available


    August 2021
  116. HIROSE W, Harigai M, Amano K, Hidaka T, et al
    Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:228.
    PubMed     Abstract available


  117. TANAKA Y, Takeuchi T, Izutsu H, Kaneko Y, et al
    Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:221.
    PubMed     Abstract available


  118. WANG Y, Chen S, Zheng S, Lin J, et al
    The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical applica
    Arthritis Res Ther. 2021;23:212.
    PubMed     Abstract available


  119. COSTELLO RE, Humphreys JH, Sergeant JC, Haris M, et al
    Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the PRe-clinical EValuation of Novel Targets in RA (PRE
    Arthritis Res Ther. 2021;23:210.
    PubMed     Abstract available


  120. WESTERLIND H, Palmqvist I, Saevarsdottir S, Alfredsson L, et al
    Is tea consumption associated with reduction of risk of rheumatoid arthritis? A Swedish case-control study.
    Arthritis Res Ther. 2021;23:209.
    PubMed     Abstract available


  121. TRANG DAMT, Okamura K, Suto T, Sakane H, et al
    Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?
    Arthritis Res Ther. 2021;23:206.
    PubMed     Abstract available


    July 2021
  122. AJEGANOVA S, Andersson MLE, Frostegard J, Hafstrom I, et al
    Higher levels of anti-phosphorylcholine autoantibodies in early rheumatoid arthritis indicate lower risk of incident cardiovascular events.
    Arthritis Res Ther. 2021;23:201.
    PubMed     Abstract available


  123. IWAMOTO N, Sato S, Kurushima S, Michitsuji T, et al
    Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:197.
    PubMed     Abstract available


  124. MINAMINO H, Katsushima M, Fujita Y, Hashimoto M, et al
    Comment on "Urinary sodium-to-potassium ratio associates with hypertension and current disease activity in patients with rheumatoid arthritis: a cross-sectional study": authors' reply.
    Arthritis Res Ther. 2021;23:195.
    PubMed    


  125. STOCKFELT M, Lundell AC, Hetland ML, Ostergaard M, et al
    Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial.
    Arthritis Res Ther. 2021;23:189.
    PubMed     Abstract available


  126. ANDONIAN BJ, Johannemann A, Hubal MJ, Pober DM, et al
    Altered skeletal muscle metabolic pathways, age, systemic inflammation, and low cardiorespiratory fitness associate with improvements in disease activity following high-intensity interval training in persons with rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:187.
    PubMed     Abstract available


  127. MESSELINK MA, Roodenrijs NMT, van Es B, Hulsbergen-Veelken CAR, et al
    Identification and prediction of difficult-to-treat rheumatoid arthritis patients in structured and unstructured routine care data: results from a hackathon.
    Arthritis Res Ther. 2021;23:184.
    PubMed     Abstract available


  128. JUNG SY, Koh JH, Kim KJ, Park YW, et al
    Switching from TNFalpha inhibitor to tacrolimus as maintenance therapy in rheumatoid arthritis after achieving low disease activity with TNFalpha inhibitors and methotrexate: 24-week result from a non-randomized, prospective, active-controlled trial.
    Arthritis Res Ther. 2021;23:182.
    PubMed     Abstract available


  129. CORRADO A, Rotondo C, Mele A, Cici D, et al
    Influence of glucocorticoid treatment on trabecular bone score and bone remodeling regulators in early rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:180.
    PubMed     Abstract available


  130. KOO BS, Eun S, Shin K, Yoon H, et al
    Machine learning model for identifying important clinical features for predicting remission in patients with rheumatoid arthritis treated with biologics.
    Arthritis Res Ther. 2021;23:178.
    PubMed     Abstract available


  131. PARK JK, Shon S, Yoo HJ, Suh DH, et al
    Inhibition of histone deacetylase 6 suppresses inflammatory responses and invasiveness of fibroblast-like-synoviocytes in inflammatory arthritis.
    Arthritis Res Ther. 2021;23:177.
    PubMed     Abstract available


  132. CHO SK, Kim H, Lee J, Nam E, et al
    Effectiveness of bazedoxifene in preventing glucocorticoid-induced bone loss in rheumatoid arthritis patients.
    Arthritis Res Ther. 2021;23:176.
    PubMed     Abstract available


    June 2021
  133. MAARSEVEEN TD, Maurits MP, Niemantsverdriet E, van der Helm-van Mil AHM, et al
    Handwork vs machine: a comparison of rheumatoid arthritis patient populations as identified from EHR free-text by diagnosis extraction through machine-learning or traditional criteria-based chart review.
    Arthritis Res Ther. 2021;23:174.
    PubMed     Abstract available


  134. EBERHARD A, Bergman S, Mandl T, Olofsson T, et al
    Predictors of unacceptable pain with and without low inflammation over 5 years in early rheumatoid arthritis-an inception cohort study.
    Arthritis Res Ther. 2021;23:169.
    PubMed     Abstract available


  135. HUR B, Gupta VK, Huang H, Wright KA, et al
    Plasma metabolomic profiling in patients with rheumatoid arthritis identifies biochemical features predictive of quantitative disease activity.
    Arthritis Res Ther. 2021;23:164.
    PubMed     Abstract available


  136. DEMORUELLE MK, Wang H, Davis RL, Visser A, et al
    Anti-peptidylarginine deiminase-4 antibodies at mucosal sites can activate peptidylarginine deiminase-4 enzyme activity in rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:163.
    PubMed     Abstract available


  137. FERRAZ-AMARO I, Corrales A, Quevedo-Abeledo JC, Vegas-Revenga N, et al
    Disease activity influences the reclassification of rheumatoid arthritis into very high cardiovascular risk.
    Arthritis Res Ther. 2021;23:162.
    PubMed     Abstract available


  138. GIOLLO A, Cioffi G, Ognibeni F, Orsolini G, et al
    Tumour necrosis factor inhibitors reduce aortic stiffness progression in patients with long-standing rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:158.
    PubMed     Abstract available


  139. MIYAZAKI Y, Nakano K, Nakayamada S, Kubo S, et al
    Serum TNFalpha levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study.
    Arthritis Res Ther. 2021;23:154.
    PubMed     Abstract available


    May 2021
  140. RICHTER JG, Chehab G, Schwartz C, Ricken E, et al
    The PICASO cloud platform for improved holistic care in rheumatoid arthritis treatment-experiences of patients and clinicians.
    Arthritis Res Ther. 2021;23:151.
    PubMed     Abstract available


  141. MATSUMOTO H, Fujita Y, Matsuoka N, Temmoku J, et al
    Serum checkpoint molecules in patients with IgG4-related disease (IgG4-RD).
    Arthritis Res Ther. 2021;23:148.
    PubMed     Abstract available


  142. OLIVER J, Nair N, Orozco G, Smith S, et al
    Correction to: Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment.
    Arthritis Res Ther. 2021;23:139.
    PubMed    


    April 2021
  143. JIN S, Li M, Wang Q, Zeng X, et al
    Bone mineral density and microarchitecture among Chinese patients with rheumatoid arthritis: a cross-sectional study with HRpQCT.
    Arthritis Res Ther. 2021;23:127.
    PubMed     Abstract available


  144. SEGU-VERGES C, Coma M, Kessel C, Smeets S, et al
    Application of systems biology-based in silico tools to optimize treatment strategy identification in Still's disease.
    Arthritis Res Ther. 2021;23:126.
    PubMed     Abstract available


  145. KIM KW, Kim BM, Won JY, Min HK, et al
    Regulation of osteoclastogenesis by mast cell in rheumatoid arthritis.
    Arthritis Res Ther. 2021;23:124.
    PubMed     Abstract available


  146. COMBE B, Allanore Y, Alten R, Caporali R, et al
    Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials.
    Arthritis Res Ther. 2021;23:119.
    PubMed     Abstract available


  147. JINNO S, Onishi A, Dubreuil M, Hashimoto M, et al
    Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study.
    Arthritis Res Ther. 2021;23:116.
    PubMed     Abstract available


  148. ZHU J, Niu Z, Alfredsson L, Klareskog L, et al
    Age at menarche, age at natural menopause, and risk of rheumatoid arthritis - a Mendelian randomization study.
    Arthritis Res Ther. 2021;23:108.
    PubMed     Abstract available


  149. MATSUMOTO Y, Shivappa N, Sugioka Y, Tada M, et al
    Change in dietary inflammatory index score is associated with control of long-term rheumatoid arthritis disease activity in a Japanese cohort: the TOMORROW study.
    Arthritis Res Ther. 2021;23:105.
    PubMed     Abstract available


  150. AKGUL A, Maddaloni M, Jun SM, Nelson AS, et al
    Stimulation of regulatory T cells with Lactococcus lactis expressing enterotoxigenic E. coli colonization factor antigen 1 retains salivary flow in a genetic model of Sjogren's syndrome.
    Arthritis Res Ther. 2021;23:99.
    PubMed     Abstract available


    March 2021
  151. WAN L, Gao Y, Gu J, Chi H, et al
    Total metabolic lesion volume of lymph nodes measured by (18)F-FDG PET/CT: a new predictor of macrophage activation syndrome in adult-onset Still's disease.
    Arthritis Res Ther. 2021;23:97.
    PubMed     Abstract available


    February 2021
  152. LIU M, Xie Z, Sun G, Chen L, et al
    Macrophage migration inhibitory factor may play a protective role in osteoarthritis.
    Arthritis Res Ther. 2021;23:59.
    PubMed     Abstract available


  153. NOWELL WB, Gavigan K, Kannowski CL, Cai Z, et al
    Which patient-reported outcomes do rheumatology patients find important to track digitally? A real-world longitudinal study in ArthritisPower.
    Arthritis Res Ther. 2021;23:53.
    PubMed     Abstract available


    January 2021
  154. HEMSHEKHAR M, Anaparti V, El-Gabalawy H, Mookherjee N, et al
    A bioavailable form of curcumin, in combination with vitamin-D- and omega-3-enriched diet, modifies disease onset and outcomes in a murine model of collagen-induced arthritis.
    Arthritis Res Ther. 2021;23:39.
    PubMed     Abstract available


  155. SOLOMON DH, Xu C, Collins J, Kim SC, et al
    The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy.
    Arthritis Res Ther. 2021;23:26.
    PubMed     Abstract available


  156. MURRAY K, Turk M, Alammari Y, Young F, et al
    Long-term remission and biologic persistence rates: 12-year real-world data.
    Arthritis Res Ther. 2021;23:25.
    PubMed     Abstract available


    April 2020
  157. TUNCEL J, Holmberg J, Haag S, Hopkins MH, et al
    Self-reactive T cells induce and perpetuate chronic relapsing arthritis.
    Arthritis Res Ther. 2020;22:95.
    PubMed     Abstract available


  158. YATES M, Bechman K, Dennison EM, MacGregor AJ, et al
    Data quality predicts care quality: findings from a national clinical audit.
    Arthritis Res Ther. 2020;22:87.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Rheumatoid Arthritis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: